PDF4PRO ⚡AMP

Modern search engine that looking for books and documents around the web

Example: barber

Reference ID: 4036863

← Back to document page

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use CONCERTA safely and effectively. See full prescribing information for CONCERTA . CONCERTA (methylphenidate HCl) Extended-Release Tablets CII Initial Approval: 2000 WARNING: DRUG DEPENDENCE See full prescribing information for complete boxed warning.

Adults 18-65 years of age 18 or 36 mg/day 18 mg - 72 mg/day . 2.3 Patients Currently Using Methylphenidate . The recommended dose of CONCERTA for patients who are currently taking methylphenidate twice daily or three times daily at doses of 10 to 60 mg/day is provided in Table 2. Dosing recommendations are based on current dose regimen and clinical

  60 mg

Download Reference ID: 4036863

Information

Domain:

Source:

Link to this page:

Please notify us if you found a problem with this document:

Spam in document Broken preview Other abuse

Documents from same domain

Effexor (venlafaxine hydrochloride) Tablets …

www.accessdata.fda.gov

Effexor ® (venlafaxine hydrochloride) Tablets Rx only . Suicidality and Antidepressant Drugs Antidepressants increased the risk compared …

  Tablets, Antidepressant, Effexor, Venlafaxine hydrochloride, Venlafaxine, Hydrochloride

Reference ID: 3101735 - Food and Drug …

www.accessdata.fda.gov

Docetaxel Injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer.

  Drug, Food, Food and drug

Cytotec® - Food and Drug Administration

www.accessdata.fda.gov

cytotec® (misoprostol) warnings cytotec (misoprostol) administration to women who are pregnant can cause abortion, premature birth, or birth defects.

  Administration, Drug, Food and drug administration, Food, Cytotec

HIGHLIGHTS OF PRESCRIBING INFORMATION …

www.accessdata.fda.gov

weakness, diplopia, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties. These symptoms . FULL …

  Breathing

Namenda XR (memantine hydrochloride) capsules …

www.accessdata.fda.gov

The most commonly observed adverse reactions seen in patients administered NAMENDA XR in the controlled clinical trial, defined as those occurring at a frequency of at least 5% in the

  Clinical, Capsule, Hydrochloride, Namenda xr, Namenda, Memantine hydrochloride, Memantine

FOR INTRAVENOUS USE ONLY - Food and Drug …

www.accessdata.fda.gov

NDA 50-706/S-022 Page 3 MERREM® I.V. (meropenem for injection) FOR INTRAVENOUS USE ONLY To reduce the development of drug-resistant bacteria and maintain the effectiveness of

  Drug, Food, Food and drug, Only, Intravenous, For intravenous use only

NOT FOR USE IN NEONATES CONTAINS BENZYL …

www.accessdata.fda.gov

Depo-Medrol® methylprednisolone acetate injectable suspension, USP NOT FOR USE IN NEONATES CONTAINS BENZYL ALCOHOL . Not For Intravenous Use . DESCRIPTION

  Alcohols, Neonates, Contains, In neonates contains benzyl, Benzyl, In neonates contains benzyl alcohol

HIGHLIGHTS OF PRESCRIBING INFORMATION …

www.accessdata.fda.gov

Dacogen is indicated for treatment of patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and …

Venofer - Food and Drug Administration

www.accessdata.fda.gov

NDA 21-135/S-017 Page 3 Venofer ® (iron sucrose injection, USP) Rx Only DESCRIPTION Venofer® (iron sucrose injection, USP) is a brown, sterile, aqueous, complex of …

  Administration, Drug, Food and drug administration, Food, Only, Venofer

Diphenhydramine Hydrochloride Injection

www.accessdata.fda.gov

HOW SUPPLIED Diphenhydramine Hydrochloride Injection, USP is a clear and colorless solution available as: 50 mg/mL in a 1 mL prefilled single-use syringe.

  Diphenhydramine

Related documents

ENDOCRINE TEST PROTOCOLS - BC Children’s

www.bcchildrens.ca

*60 min " " For the high-dose ACTH test, blood is generally obtained at 0 and 60 min; for the low-dose test, blood is generally obtained at 0, 20 and 30 min. At time test is booked, determine if additional blood is to be collected for each sample and if ACTH is to be collected on …

Ciprofloxacin - Antimicrobe

www.antimicrobe.org

Tablets: 100mg, 250mg, 500mg, 750mg, 500mg extended release tabs, 1000mg extended release tablets IV: 200mg, 400mg Suspension: 250mg/5ml and 500mg/5ml (both in 100ml bottles) Adult patients: Lower respiratory tract infections: 500-750mg PO q12h / 400mg q8-12h IV x 7-14 days Acute sinusitis: 500mg PO q12h / 400mg q12h IV x 10 days

  Release, Tablets, Release tablets, Ciprofloxacin

Related search queries

Ciprofloxacin, Tablets, Release, Release tablets